Operating
Impairment Charges
Bristol-Myers Squibb Impairment Charges increased by 1305.0% to $1.95B in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 6634.5%, from $29.00M to $1.95B. Over 3 years (FY 2021 to FY 2024), Impairment Charges shows an upward trend with a 34.9% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryCapital Allocation
SignalLower is better
VolatilityVolatile
First reportedQ1 2015
Last reportedQ4 2025
How to read this metric
High impairment charges suggest poor capital allocation or a decline in the competitive value of the company's assets.
Detailed definition
Impairment charges are non-cash write-downs taken when the carrying value of an asset exceeds its fair market value. Thi...
Peer comparison
Common in industries with high intangible asset bases, such as pharma and consumer goods.
Metric ID:
cf_impairment_chargesHistorical Data
15 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $240.00M | $613.00M | $15.00M | $41.00M | $42.00M | $61.00M | $35.00M | $20.00M | $47.00M | $159.00M | $29.00M | $1.00M | $870.00M | $139.00M | $1.95B |
| QoQ Change | — | +155.4% | -97.6% | +173.3% | +2.4% | +45.2% | -42.6% | -42.9% | +135.0% | +238.3% | -81.8% | -96.6% | >999% | -84.0% | >999% |
| YoY Change | — | — | — | — | -82.5% | -90.0% | +133.3% | -51.2% | +11.9% | +160.7% | -17.1% | -95.0% | >999% | -12.6% | >999% |
Range$1.00M – $1.95B
CAGR+82.0%
Avg YoY Growth+758.5%
Median YoY Growth-12.6%
Impairment Charges at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's impairment charges?
- Bristol-Myers Squibb (BMY) reported impairment charges of $1.95B in Q4 2024.
- How has Bristol-Myers Squibb's impairment charges changed year-over-year?
- Bristol-Myers Squibb's impairment charges increased by 6634.5% year-over-year, from $29.00M to $1.95B.
- What is the long-term trend for Bristol-Myers Squibb's impairment charges?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's impairment charges has grown at a 34.9% compound annual growth rate (CAGR), from $1.21B to $2.96B.
- What does impairment charges mean?
- A non-cash charge taken when an asset is determined to be worth less than its recorded value.